Dr. Ellin Berman, MD

Dr. Berman practices at Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center.

Dr. Berman's NPI, 1083685861, was assigned on January 30, 2006. Dr. Berman graduated from Harvard Medical School in 1977. Dr. Berman holds New York license 151251.

Dr. Berman's primary practice is Memorial Sloan Kettering Cancer Center, at 1275 York Avenue, New York, NY 10065.

Dr. Berman's primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. The medical group on file is Memorial Hematology Lymphoma Group. Dmand AI also links Dr. Berman to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Berman practices, 3 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Berman's primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Dr. Berman is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Berman's licenses on file in 3 states: New York, Florida and New Jersey.

Dmand AI lists chronic anemia, chronic leukemia, lymphoma and multiple myeloma among the conditions Dr. Berman treats.

CMS data shows 373 Medicare services from Dr. Berman across 5 procedure codes in 2024, for 151 Medicare patients. Medicare paid $37,075 for them. Every service was in an office.

CMS counts 151 Medicare patients who saw Dr. Berman in 2024. The largest group is 75 to 84, with 69 patients. 75% of them have high cholesterol, and 74% have high blood pressure. 11% are also on Medicaid. Their average risk score is 2.29, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Berman's median patient age at 74, with 47% women.

In 2024, Dr. Berman wrote 123 Medicare Part D claims for 36 patients. 41% of them were for generic drugs. CMS names the drug for 60 of them, across 2 drugs with 11 or more claims each, at $604,881 in total drug cost. In 2023, CMS named 72 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 80 out of 100 for Dr. Berman for performance year 2024, reported as part of a group. Dr. Berman accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Berman as offering telehealth.

Dmand AI links 97 papers to Dr. Berman, published from 2006 to 2025. 2018 was the busiest year, with 9. The most frequent topics are Leukemia, Myeloid, Acute, Antineoplastic Combined Chemotherapy Protocols and Leukemia, Myelogenous, Chronic, BCR-ABL Positive. Dr. Berman has published most often in Blood. Dr. Berman's most frequent co-authors are Michael Andreeff, MD, Jessica Kaplan Altman, MD and Martin S. Tallman, MD.

Dmand AI links Dr. Berman to 6 clinical trials, 3 of them phase 2 studies. 1 is still active or recruiting. Conditions studied include Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute and Leukemia, Myeloid. Memorial Sloan Kettering Cancer Center sponsors the most, 3.

CMS Open Payments shows 21 general payments to Dr. Berman from 7 drug and device companies from 2017 to 2025. Consulting fees make up the largest share, 92% of the total. Novartis Pharmaceuticals Corporation paid the most, $12,839. It also lists 34 research payments totaling $8,198 from 2019 to 2021.

Dmand AI lists 2 awards for Dr. Berman, most recently Top Doctors: New York Metro Area in 2014.

Dr. Berman graduated from Harvard Medical School in 1977. Dr. Berman is a member of ASCO.

Dr. Berman is in network with 13 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.